新辅助化疗在非局部进展性早期宫颈癌应用的临床分析(附67例报告)

目的探讨如何进一步改善非局部进展性早期宫颈癌的预后。方法对2005年7月至2010年3月我院收治的67例非局部进展性早期宫颈癌患者的病历资料作回顾性分析。根据患者术后病理结果,分析影响预后的重要因素——脉管浸润和淋巴结转移,寻找与其关联的临床特征。结果肿瘤大小及间质浸润深度是非局部进展性早期宫颈癌脉管浸润及淋巴结转移的高危因素(P<0.05),年龄、病理类型及组织学分级均不是高危因素(P>0.05)。结论对肿瘤最大直径2～4cm或间质浸润深度超过1/2的非局部进展性早期宫颈癌患者可考虑行术前新辅助化疗,以改善预后。

Clinical analysis of application of neoadjuvant chemotherapy for non-locally advanced early-stage cervical cancer

Objective To study how to improve the prognosis of non-locally advanced early-stage cervical cancer.Methods The case data of 67 non-locally advanced early-stage cervical cancer patients from July 2005 to March 2010 were studied retrospectively.According to these patients pathologic results,the important influential factors of prognostic,including lymphovascular space invasion(LVSI) and lymph node metastasis,were analyzed.The clinic features of those high risk patients were sought for.Results Tumor diameter and stroma invasion depth were high risk influential factors(P<0.05).Age,pathologic category and histological differentiation were not influential factors for LVSI and lymph node metastasis(P>0.05).Conclusion Those patients with maximum cervical cancer diameter from 2 centimeters to 4 centimeters or stroma invasion more than 1/2 can be interfered in by neoadjuvant chemotherapy to expectedly improve the prognosis of non-locally advanced early-stage cervical cancer.